| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
1-Deoxymannojirimycin HCl targets mannosidase I, an α-1,2-mannosidase that catalyzes the removal of mannose residues from N-linked glycoproteins during glycoprotein processing in the endoplasmic reticulum. By inhibiting mannosidase I, the compound blocks the early steps of N-glycan processing, leading to the accumulation of high-mannose glycoproteins. This inhibition is used to study the role of N-glycosylation in protein folding, trafficking, and function【1】.
|
|---|---|
| ln Vitro |
In vitro, 1-Deoxymannojirimycin HCl is an inhibitor of mannosidase I that is used in glycobiology research【1】. By blocking mannosidase I activity, the compound prevents the trimming of mannose residues from N-linked glycoproteins, leading to the accumulation of high-mannose glycoproteins. This allows researchers to study the role of N-glycosylation in protein folding, trafficking, and function in various cell types【1】.
|
| ln Vivo |
In vivo, 1-Deoxymannojirimycin HCl is used in research to study glycoprotein processing and the role of glycosylation in various biological processes. However, the compound is not administered as a therapeutic agent. Its primary use is in biochemical and cell biology studies to investigate the function of N-linked glycosylation【1】.
|
| Enzyme Assay |
For in vitro enzyme assays, recombinant mannosidase I or mannosidase I-containing cell lysates are incubated with a fluorogenic or chromogenic substrate (such as p-nitrophenyl-α-D-mannopyranoside) in assay buffer. The test compound is added at various concentrations (0.1-1000 µM). Enzyme activity is measured by monitoring absorbance or fluorescence over time. IC50 values are calculated by fitting dose-response curves【1】.
|
| Cell Assay |
For cell-based assays, cells are treated with 1-Deoxymannojirimycin HCl at concentrations ranging from 0.1-1000 µM for 24-72 hours. Glycoprotein processing is assessed by analyzing the glycosylation status of specific proteins by Western blotting or by using lectin binding assays. Protein trafficking and function can be assessed using functional assays【1】.
|
| Animal Protocol |
For in vivo studies, 1-Deoxymannojirimycin HCl is not typically administered to animals as a therapeutic agent. It may be used in ex vivo preparations or in cell culture studies to investigate glycoprotein processing. Its primary use is in in vitro glycobiology research【1】.
|
| ADME/Pharmacokinetics |
1-Deoxymannojirimycin HCl is soluble in water and DMSO. Storage is recommended at -20°C for long-term stability. The compound is for research use only and is not intended for human or veterinary use. Standard laboratory safety precautions should be followed when handling this compound【1】.
|
| Toxicity/Toxicokinetics |
1-Deoxymannojirimycin HCl is an inhibitor of mannosidase I and is generally considered to have low toxicity at the concentrations used for glycobiology studies. However, it may affect glycoprotein processing and should be handled with care. Standard laboratory safety precautions should be followed when handling this compound【1】.
|
| References |
|
| Additional Infomation |
1-Deoxymannojirimycin HCl is a mannosidase I inhibitor used in glycobiology research to study the role of N-glycosylation in protein folding, trafficking, and function【1】. It is a research tool and is not approved for clinical use.
|
| Molecular Formula |
C6H13NO4.HCL
|
|---|---|
| Molecular Weight |
199.63266
|
| Exact Mass |
199.061
|
| CAS # |
73465-43-7
|
| PubChem CID |
11390018
|
| Appearance |
Off-white to gray solid powder
|
| Melting Point |
183-185ºC
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
132
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@H]([C@H]([C@@H]([C@H](N1)CO)O)O)O.Cl
|
| InChi Key |
ZJIHMALTJRDNQI-MVNLRXSJSA-N
|
| InChi Code |
InChI=1S/C6H13NO4.ClH/c8-2-3-5(10)6(11)4(9)1-7-3;/h3-11H,1-2H2;1H/t3-,4-,5-,6-;/m1./s1
|
| Chemical Name |
(2R,3R,4R,5R)-2-(hydroxymethyl)piperidine-3,4,5-triol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~500.93 mM)
DMSO : ~50 mg/mL (~250.46 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.5 mg/mL (17.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.5 mg/mL (17.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.5 mg/mL (17.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (500.93 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0093 mL | 25.0463 mL | 50.0927 mL | |
| 5 mM | 1.0019 mL | 5.0093 mL | 10.0185 mL | |
| 10 mM | 0.5009 mL | 2.5046 mL | 5.0093 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
